Nichtenzymatische Glykierung und oxidativer Streß bei chronischen Erkrankungen und Diabetes mellitus

[1]  T. Luther,et al.  Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE. , 1997, Circulation.

[2]  T. Luther,et al.  Advanced Glycation End Product-Induced Activation of NF-κB is Suppressed by α-Lipoic Acid in Cultured Endothelial Cells , 1997, Diabetes.

[3]  R. Bucala,et al.  Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Z. Makita,et al.  Progression of Nephropathy in Spontaneous Diabetic Rats Is Prevented by OPB-9195, a Novel Inhibitor of Advanced Glycation , 1997, Diabetes.

[5]  H. Vlassara.  Pathogenesis of diabetic nephropathy, advanced glcation and new therapy , 1997, Medizinische Klinik.

[6]  J. Wautier,et al.  Advanced glycation end products, oxidant stress and vascular lesions , 1997, European journal of clinical investigation.

[7]  J. Thome,et al.  Advanced glycation endproducts in ageing and Alzheimer's disease , 1997, Brain Research Reviews.

[8]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[9]  H. Vlassara.  Advanced glycation end-products and atherosclerosis. , 1996, Annals of medicine.

[10]  Alan W. Stitt,et al.  Molecular identity and cellular distribution of advanced glycation endproduct receptors: relationship of p60 to OST-48 and p90 to 80K-H membrane proteins. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Miyata,et al.  The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE-beta2microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. Implications for the pathogenesis of dialysis-related amyloidosis. , 1996, The Journal of clinical investigation.

[12]  X. Chen,et al.  RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.

[13]  M. Mattson,et al.  Amyloid ox–tox transducers , 1996, Nature.

[14]  David H. Williams,et al.  Phosphorylation of SLP-76 by the ZAP-70 Protein-tyrosine Kinase Is Required for T-cell Receptor Function* , 1996, The Journal of Biological Chemistry.

[15]  M. Brownlee.  Advanced glycation end products in diabetic complications , 1996 .

[16]  J. Bernhagen,et al.  An agent cleaving glucose-derived protein crosslinks in vitro and in vivo , 1996, Nature.

[17]  K. Drickamer.  Breaking the curse of the AGEs , 1996, Nature.

[18]  K. Schubert,et al.  [Accumulation of AGE (advanced glycosylation end-products) in the aging process, in diabetes mellitus and in chronic renal failure]. , 1996, Medizinische Klinik.

[19]  S. Grimm,et al.  Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis , 1996, The Journal of cell biology.

[20]  H. Vlassara,et al.  Protein glycation in the kidney: role in diabetes and aging. , 1996, Kidney international.

[21]  A. Folsom,et al.  Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. , 1996, The New England journal of medicine.

[22]  E. Stier,et al.  Receptors for advanced glycation end-products (AGE)—expression by endothelial cells in non-diabetic uraemic patients , 1996 .

[23]  R. Bucala,et al.  Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  T. Lyons,et al.  The Advanced Glycation End Product, N-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation Reactions (*) , 1996, The Journal of Biological Chemistry.

[25]  F. Kelly,et al.  Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) , 1996, The Lancet.

[26]  M. Brownlee,et al.  BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells. , 1996, The Journal of clinical investigation.

[27]  G. Paolisso,et al.  Oxidative Stress and Diabetic Vascular Complications , 1996, Diabetes Care.

[28]  T. Nicotera,et al.  Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.

[29]  M. Hanefeld,et al.  Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). , 1995, Diabetologia.

[30]  J. Baynes,et al.  Pathways of formation of glycoxidation products during glycation of collagen. , 1995, Biochemistry.

[31]  V. Monnier,et al.  Protein modification by the degradation products of ascorbate: formation of a novel pyrrole from the Maillard reaction of L-threose with proteins. , 1995, Biochimica et biophysica acta.

[32]  J. Chen,et al.  The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin , 1995, The Journal of Biological Chemistry.

[33]  Yong Ming Li,et al.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation–modified proteins to a conserved motif , 1995, Nature Medicine.

[34]  A. Schmidt,et al.  The dark side of glucose , 1995, Nature Medicine.

[35]  S. Kuwajima,et al.  Advanced glycation endproducts and diabetic nephropathy. , 1995, Journal of diabetes and its complications.

[36]  D. Betteridge,et al.  Elevated Levels of Authentic Plasma Hydroperoxides in NIDDM , 1995, Diabetes.

[37]  Yong Ming Li,et al.  Identification of Galectin-3 As a High-Affinity Binding Protein for Advanced Glycation End Products (AGE): A New Member of the AGE-Receptor Complex , 1995, Molecular medicine.

[38]  E. Ritz,et al.  Expression of receptors for advanced glycosylated end-products in renal disease. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[39]  H. Vlassara.  Advanced glycation in diabetic renal and vascular disease. , 1995, Kidney international. Supplement.

[40]  M. Cotter,et al.  Neurovascular dysfunction in diabetic rats. Potential contribution of autoxidation and free radicals examined using transition metal chelating agents. , 1995, The Journal of clinical investigation.

[41]  H. Tritschler,et al.  Lipoic Acid Improves Nerve Blood Flow, Reduces Oxidative Stress, and Improves Distal Nerve Conduction in Experimental Diabetic Neuropathy , 1995, Diabetes Care.

[42]  A. Gugliucci,et al.  Histones from diabetic rats contain increased levels of advanced glycation end products. , 1995, Biochemical and biophysical research communications.

[43]  J. Zweier,et al.  Non-enzymatically glycated tau in Alzheimer's disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide , 1995, Nature Medicine.

[44]  S. Jimi,et al.  Nonenzymatic glycation and extractability of collagen in human atherosclerotic plaques. , 1995, Atherosclerosis.

[45]  T. Niwa,et al.  Advanced Glycation End Products Are Associated with 2-Microglobulin Amyloidosis , 1995 .

[46]  A. Griesmacher,et al.  Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. , 1995, The American journal of medicine.

[47]  T. Koschinsky,et al.  Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[48]  M. Cybulsky,et al.  Advanced Glycation Endproducts Promote Adhesion Molecule (VCAM-1, ICAM-1) Expression and Atheroma Formation in Normal Rabbits , 1995, Molecular medicine.

[49]  V. Monnier,et al.  Mechanism of Protein Modification by Glyoxal and Glycolaldehyde, Reactive Intermediates of the Maillard Reaction (*) , 1995, The Journal of Biological Chemistry.

[50]  F. Lottspeich,et al.  Purification and partial amino acid sequencing of a fructosyllysine-specific binding protein from cell membranes of the monocyte-like cell line U937. , 1995, Biochimica et biophysica acta.

[51]  J. Baynes,et al.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. , 1995, Biochemistry.

[52]  G. Otto,et al.  Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. , 1995, The American journal of pathology.

[53]  S. Parthasarathy,et al.  Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[54]  R. Bucala,et al.  Identification of N2-(1-carboxyethyl)guanine (CEG) as a guanine advanced glycosylation end product. , 1995, Biochemistry.

[55]  R. Galassi,et al.  Increased susceptibility to lipid oxidation of low-density lipoproteins and erythrocyte membranes from diabetic patients. , 1994, Metabolism: clinical and experimental.

[56]  P. Seth,et al.  Altered platelet functions in non-insulin-dependent diabetes mellitus (NIDDM). , 1994, Thrombosis research.

[57]  Yong Ming Li,et al.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[58]  A. Sinclair,et al.  Low Plasma Ascorbate Levels in Patients with Type 2 Diabetes Mellitus Consuming Adequate Dietary Vitamin C , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[59]  P. Syrris,et al.  Carnosine protects proteins against in vitro glycation and cross-linking. , 1994, Biochemical Society transactions.

[60]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[61]  G. Striker,et al.  Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[62]  S. Grundy,et al.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Lyons,et al.  3-Deoxyfructose Concentrations are Increased in Human Plasma and Urine in Diabetes , 1994, Diabetes.

[64]  A. Schmidt,et al.  Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  M. Brownlee,et al.  Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. A model for intracellular glycosylation in diabetes. , 1994, The Journal of clinical investigation.

[66]  C. Bravi,et al.  Effect of aldose reductase inhibition on glutathione redox status in erythrocytes of diabetic patients. , 1994, Metabolism: clinical and experimental.

[67]  Paul J Thornalley,et al.  Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. , 1994, Clinical science.

[68]  E. Friedman,et al.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure , 1994, The Lancet.

[69]  J. Baynes,et al.  Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction , 1994, Diabetes.

[70]  M. Simionescu,et al.  The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. , 1994, The Journal of biological chemistry.

[71]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[72]  H. Seo,et al.  Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. , 1994, The Journal of clinical investigation.

[73]  R. Bucala,et al.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[74]  S. Amemiya,et al.  Antioxidants in the serum of children with insulin-dependent diabetes mellitus. , 1993, Free radical biology & medicine.

[75]  Y. Zou,et al.  Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. , 1993, The American journal of pathology.

[76]  S. Wolff,et al.  Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. , 1993, Biochemical pharmacology.

[77]  M. Huijberts,et al.  Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. , 1993, The Journal of clinical investigation.

[78]  R. Bucala,et al.  Lipid advanced glycosylation: pathway for lipid oxidation in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[79]  T. Lyons,et al.  Accumulation of Maillard reaction products in skin collagen in diabetes and aging. , 1993, The Journal of clinical investigation.

[80]  M. Mcdaniel,et al.  Prevention of Diabetic Vascular Dysfunction by Guanidines: Inhibition of Nitric Oxide Synthase Versus Advanced Glycation End-Product Formation , 1993, Diabetes.

[81]  A. Ferro-Luzzi,et al.  Salicylate hydroxylation as an early marker of in vivo oxidative stress in diabetic patients. , 1992, Free radical biology & medicine.

[82]  E. Friedman,et al.  Hemoglobin-AGE: a circulating marker of advanced glycosylation. , 1992, Science.

[83]  M. Cotter,et al.  Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats , 1992, Diabetologia.

[84]  C. Barnes,et al.  X-Ray Structures of a 3-Amino-5- and a 3-Amino-6-Substituted Triazine, Produced as a Result of a Reaction of 3-Deoxy-D-Erythro-Hexos-2-Ulose (3-Deoxyglucosone) with Aminoguanidine , 1992 .

[85]  V. Monnier,et al.  Maillard Reaction-Mediated Molecular Damage to Extracellular Matrix and Other Tissue Proteins in Diabetes, Aging, and Uremia , 1992, Diabetes.

[86]  J. Witztum,et al.  Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[87]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[88]  W. Hurley,et al.  Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. , 1992, The Journal of biological chemistry.

[89]  R. Bucala,et al.  Immunochemical detection of advanced glycosylation end products in vivo. , 1992, The Journal of biological chemistry.

[90]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[91]  M. Brownlee,et al.  Mechanistic Studies of Advanced Glycosylation End Product Inhibition by Aminoguanidine , 1992, Diabetes.

[92]  H. Hammes,et al.  Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Z. Makita,et al.  Radioreceptor Assay for Advanced Glycosylation End Products , 1991, Diabetes.

[94]  G. Jerums,et al.  Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat , 1991, Diabetes.

[95]  E. Ellis,et al.  Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. , 1991, Metabolism: clinical and experimental.

[96]  E. Friedman,et al.  Advanced glycosylation end products in patients with diabetic nephropathy. , 1991, The New England journal of medicine.

[97]  M. Suthanthiran,et al.  Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins , 1991, The Journal of experimental medicine.

[98]  P. Low,et al.  Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[99]  V. Monnier,et al.  Mechanism of formation of the Maillard protein cross-link pentosidine. Glucose, fructose, and ascorbate as pentosidine precursors. , 1991, The Journal of biological chemistry.

[100]  J. Baynes,et al.  Formation of pentosidine during nonenzymatic browning of proteins by glucose. Identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. , 1991, The Journal of biological chemistry.

[101]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[102]  A. Sinclair,et al.  Disturbed handling of ascorbic acid in diabetic patients with and without microangiopathy during high dose ascorbate supplementation , 1991, Diabetologia.

[103]  T. Lyons,et al.  Age-dependent accumulation of N epsilon-(carboxymethyl)lysine and N epsilon-(carboxymethyl)hydroxylysine in human skin collagen. , 1991, Biochemistry.

[104]  T. Lyons,et al.  Effect of Diabetes and Aging on Carboxymethyllysine Levels in Human Urine , 1991, Diabetes.

[105]  M. Brownlee,et al.  Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. , 1990, Biochemical and biophysical research communications.

[106]  J. Richardson,et al.  Reaction of ascorbate with lysine and protein under autoxidizing conditions: formation of N epsilon-(carboxymethyl)lysine by reaction between lysine and products of autoxidation of ascorbate. , 1990, Biochemistry.

[107]  A. Cerami,et al.  Isolation of Surface Binding Protein Specific for Advanced Glycosylation End Products From Mouse Macrophage-Derived Cell Line RAW 264.7 , 1990, Diabetes.

[108]  S. Wolff,et al.  Autoxidative Glycosylation and Possible Involvement of Peroxides and Free Radicals in LDL Modification by Glucose , 1990, Diabetes.

[109]  S. Wolff,et al.  Hydrogen peroxide production during experimental protein glycation , 1990, FEBS letters.

[110]  R. Rolandi,et al.  Prevention of Diabetes-Increased Aging Effect on Rat Collagen-Linked Fluorescence by Aminoguanidine and Rutin , 1990, Diabetes.

[111]  F. Ledl,et al.  Die Maillard‐Reaktion in Lebensmitteln und im menschlichen Körper – neue Ergebnisse zu Chemie, Biochemie und Medizin , 1990 .

[112]  A. J. Furth.  The maillard reaction in aging, diabetes and nutrition: edited by John W. Baynes and Vincent M. Monnier, Alan R. Liss, 1989. $85.00 (xvii + 432 pages) ISBN 0 8451 5154 1 , 1990 .

[113]  J. Harding,et al.  The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins. , 1990, Experimental eye research.

[114]  V. Monnier,et al.  End-stage renal disease and diabetes catalyze the formation of a pentose-derived crosslink from aging human collagen. , 1990, The Journal of clinical investigation.

[115]  Y. Morino,et al.  Scavenger receptor of human monocytic leukemia cell line (THP-1) and murine macrophages for nonenzymatically glycosylated proteins. , 1989, Biochimica et biophysica acta.

[116]  S. Kuwajima,et al.  Production and characterization of antibodies to advanced glycation products on proteins. , 1989, Biochemical and biophysical research communications.

[117]  K. Nicholls,et al.  Advanced glycosylation end-products in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[118]  R. Dean,et al.  Hydroxyl radical production and autoxidative glycosylation. Glucose autoxidation as the cause of protein damage in the experimental glycation model of diabetes mellitus and ageing. , 1988, The Biochemical journal.

[119]  Y. Morino,et al.  Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. , 1988, The Journal of biological chemistry.

[120]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[121]  A. Cerami,et al.  Characterization of a solubilized cell surface binding protein on macrophages specific for proteins modified nonenzymatically by advanced glycosylated end products. , 1988, Archives of biochemistry and biophysics.

[122]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[123]  A. Cerami,et al.  Specific Macrophage Receptor Activity for Advanced Glycosylation End Products Inversely Correlates With Insulin Levels In Vivo , 1988, Diabetes.

[124]  H. Vlassara,et al.  Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors , 1986, The Journal of experimental medicine.

[125]  A. Cerami,et al.  Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. , 1986, Science.

[126]  J. Baynes,et al.  Identification of N epsilon-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. , 1986, The Journal of biological chemistry.

[127]  A. Cerami,et al.  High-affinity-receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[128]  T. O'dorisio,et al.  Production of 12-Hydroxyeicosatetraenoic Acid and Vitamin E Status in Platelets from Type I Human Diabetic Subjects , 1985, Diabetes.

[129]  V. Monnier,et al.  Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. , 1981, Science.

[130]  V. J. Stevens,et al.  Diabetic cataract formation: potential role of glycosylation of lens crystallins. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[131]  H. Oxlund,et al.  Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus , 2004, Diabetologia.

[132]  H. Hammes,et al.  Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat , 2004, Diabetologia.

[133]  M. Brownlee,et al.  Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats , 2004, Diabetologia.

[134]  P. Guillausseau,et al.  Rapid Publication , 1971, Nature.

[135]  E. Ritz,et al.  Expression of receptors for advanced glycation end-products in occlusive vascular and renal disease. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[136]  N. Hotta,et al.  Role of polyol pathway in nonenzymatic glycation. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[137]  M. Brownlee,et al.  Advanced protein glycosylation in diabetes and aging. , 1995, Annual review of medicine.

[138]  P. Riederer,et al.  The cognition-enhancing drug tenilsetam is an inhibitor of protein crosslinking by advanced glycosylation , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[139]  E. Ritz,et al.  Toxicity of uraemia--does it come of AGE? , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[140]  H. Lemke.  Hypersensitivity reactions during haemodialysis: the choice of methods and assays. , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[141]  L. Packer,et al.  Lipoate prevents glucose-induced protein modifications. , 1992, Free radical research communications.

[142]  R. Bucala,et al.  Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. , 1992, Advances in pharmacology.

[143]  W. Pryor,et al.  Noninvasive measures of oxidative stress status in humans. , 1991, Free radical biology & medicine.

[144]  Njoroge Fg,et al.  The chemistry of the Maillard reaction under physiological conditions: a review. , 1989 .

[145]  M. Khatami,et al.  Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. , 1988, Life sciences.

[146]  R. Bucala,et al.  Modification of DNA by reducing sugars: a possible mechanism for nucleic acid aging and age-related dysfunction in gene expression. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[147]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .